Probi AB
STO:PROB

Watchlist Manager
Probi AB Logo
Probi AB
STO:PROB
Watchlist
Price: 350 SEK 0.29% Market Closed
Market Cap: 4B SEK

P/OCF
Price to OCF

30.2
Current
25.1
Median
21.2
Industry
Higher than median
Higher than industry value

Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.

P/OCF
30.2
=
Market Cap
4B SEK
/
Operating Cash Flow
132.3m SEK
Market Cap P/OCF
SE
Probi AB
STO:PROB
4B SEK 30.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -243 405.9
US
Abbvie Inc
NYSE:ABBV
313.6B USD 18.9
US
Amgen Inc
NASDAQ:AMGN
144.4B USD 20
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 11.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.4B USD -126.4
US
Epizyme Inc
F:EPE
94.1B EUR -462.2
AU
CSL Ltd
ASX:CSL
135.3B AUD 30.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD 18.6
US
Seagen Inc
F:SGT
39.3B EUR -74.6
NL
argenx SE
XBRU:ARGX
38.2B EUR -150.9
 
SE
Probi AB
STO:PROB
Average P/OCF: 21.5
30.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -243 405.9
US
Abbvie Inc
NYSE:ABBV
18.9
US
Amgen Inc
NASDAQ:AMGN
20
US
Gilead Sciences Inc
NASDAQ:GILD
11.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -126.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -462.2
AU
CSL Ltd
ASX:CSL
30.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -74.6
NL
argenx SE
XBRU:ARGX
Negative Multiple: -150.9

P/OCF Forward Multiples

Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/OCF
N/A
2-Years Forward
P/OCF
N/A
3-Years Forward
P/OCF
N/A